Abion, a clinical-stage oncology company specializing in precision cancer therapies, is actively seeking global partners to co-develop and commercialize ABN401 (Vabametkib) — a potent, selective, oral c-MET inhibitor currently in Phase 2 clinical development for non-small cell lung cancer (NSCLC).

Earlier this year, Abion signed a term sheet with a global pharmaceutical company headquartered in Russia, initiating a licensing deal for the Russia and CIS (Commonwealth of Independent States) markets.

The partner, which operates subsidiaries in San Diego and other key locations, also maintains a robust commercial and distribution infrastructure across Russia and CIS countries.

While specific terms remain confidential under a non-disclosure agreement, the agreement reflects the market demand and strong commercial potential of ABN401 in the region.

Importantly, this collaboration enables Abion to generate clinical data in Caucasian populations, paving the way for future expansion into U.S. and European markets. The term sheet also includes multiple development paths, including:

• ABN401 as a monotherapy
• Combination therapy with Lazertinib (licensed from Yuhan Corporation)
• Development in hepatocellular carcinoma (HCC), gastric cancer, and glioblastoma (GBM)

Abion views this partnership as a strategic milestone, validating ABN401’s versatility and potential for broader indications. The company continues to pursue multi-regional partnering strategies and is currently in discussion with major pharmaceutical companies in the U.S. and Europe for additional licensing and development opportunities.

ABN401 is designed to target MET exon 14 skipping mutations and other aberrations of the c-MET pathway. The drug is being evaluated in Phase 2 trials as both a standalone therapy and in combination with Lazertinib, with promising safety and efficacy profiles to date.

Abion will present preclinical data on the Lazertinib combination therapy at the upcoming AACR Annual Meeting in Illinois, April 2025.

Abion welcome inquiries from potential partners interested in licensing, co-development, or regional commercialization of ABN401. As the company continue expanding our global footprint, we look forward to building transformative collaborations to bring innovative treatments to patients worldwide.